JP2019503167A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019503167A5 JP2019503167A5 JP2018524281A JP2018524281A JP2019503167A5 JP 2019503167 A5 JP2019503167 A5 JP 2019503167A5 JP 2018524281 A JP2018524281 A JP 2018524281A JP 2018524281 A JP2018524281 A JP 2018524281A JP 2019503167 A5 JP2019503167 A5 JP 2019503167A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr1
- cdr3
- cdr2
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 229920001184 polypeptide Polymers 0.000 claims 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims 33
- 150000001413 amino acids Chemical class 0.000 claims 27
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 12
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 11
- 108060003951 Immunoglobulin Proteins 0.000 claims 9
- 102000018358 immunoglobulin Human genes 0.000 claims 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 7
- 230000002860 competitive effect Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000015228 acquired partial lipodystrophy Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 102000052645 human CD38 Human genes 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 208000036274 partial acquired susceptibility to lipodystrophy Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562253318P | 2015-11-10 | 2015-11-10 | |
| US62/253,318 | 2015-11-10 | ||
| PCT/EP2016/077361 WO2017081211A2 (en) | 2015-11-10 | 2016-11-10 | Antigen-binding polypeptides directed against cd38 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019503167A JP2019503167A (ja) | 2019-02-07 |
| JP2019503167A5 true JP2019503167A5 (OSRAM) | 2019-12-19 |
Family
ID=57391949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018524281A Pending JP2019503167A (ja) | 2015-11-10 | 2016-11-10 | Ｃｄ３８に対する抗原結合性ポリペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10865249B2 (OSRAM) |
| EP (1) | EP3374397A2 (OSRAM) |
| JP (1) | JP2019503167A (OSRAM) |
| CN (1) | CN108884162A (OSRAM) |
| AU (1) | AU2016352676A1 (OSRAM) |
| CA (1) | CA3004792A1 (OSRAM) |
| MA (1) | MA43219A (OSRAM) |
| WO (1) | WO2017081211A2 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3005488A1 (en) * | 2015-11-18 | 2017-05-26 | Ablynx Nv | Improved serum albumin binders |
| KR20190053835A (ko) | 2016-06-21 | 2019-05-20 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| CN114395048B (zh) | 2016-09-14 | 2025-01-28 | 特纳奥尼股份有限公司 | Cd3结合抗体 |
| CN116284402A (zh) | 2016-12-21 | 2023-06-23 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
| KR102742528B1 (ko) | 2017-06-20 | 2024-12-16 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| CA3065951A1 (en) | 2017-06-20 | 2018-12-27 | Teneoone, Inc. | Anti-bcma heavy chain-only antibodies |
| CN109232739B (zh) * | 2017-07-11 | 2021-07-20 | 北京大学深圳研究生院 | 一种抗cd38纳米抗体、编码基因及应用 |
| US11708418B2 (en) * | 2017-08-10 | 2023-07-25 | Grifols Diagnostic Solutions Inc. | Compositions, methods and/or kits comprising a recombinant human CD38- extracellular domain |
| BR112020004846A2 (pt) * | 2017-09-13 | 2020-09-15 | Teneobio, Inc. | anticorpos de cadeia pesada que se ligam a ectoenzimas |
| EP3765090A4 (en) * | 2018-03-13 | 2022-03-16 | Trillium Therapeutics Inc. | COMBINATION OF CD47 BLOCKADE THERAPY AND A CD38 ANTIBODY |
| US20210388106A1 (en) * | 2018-10-26 | 2021-12-16 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
| AU2019395841B2 (en) | 2018-12-14 | 2025-02-27 | Morphosys Ag | Antibody formulations |
| MX2021012205A (es) | 2019-04-05 | 2022-02-21 | Teneobio Inc | Anticuerpos de cadena pesada que se unen al psma. |
| JP7665538B2 (ja) | 2019-06-14 | 2025-04-21 | テネオバイオ， インコーポレイテッド | Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体 |
| JP7561364B2 (ja) * | 2020-04-30 | 2024-10-04 | 国立大学法人東北大学 | 蛍光偏光免疫分析法 |
| WO2021229104A1 (en) * | 2020-05-15 | 2021-11-18 | Université de Liège | Anti-cd38 single-domain antibodies in disease monitoring and treatment |
| CN112457401B (zh) * | 2020-10-21 | 2023-02-24 | 上海交通大学医学院附属仁济医院 | 一种诊断多发性骨髓瘤的分子影像探针 |
| WO2022094147A1 (en) * | 2020-10-28 | 2022-05-05 | City Of Hope | Bispecific anti-cd38-cd3 binders |
| US20240261446A1 (en) * | 2021-05-17 | 2024-08-08 | Université de Liège | Anti-cd38 single domain antibodies in disease monitoring and treatment |
| WO2022271987A1 (en) * | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| US20250277051A1 (en) * | 2021-08-02 | 2025-09-04 | Hangzhou Unogen Biotech, Ltd | Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof |
| CN115174413B (zh) | 2022-07-07 | 2024-08-30 | 苏州磐联集成电路科技股份有限公司 | 网状网络系统的配对切换方法 |
| US20240415974A1 (en) | 2022-12-23 | 2024-12-19 | Ablynx N.V. | Protein-based conjugation carriers |
| AR131869A1 (es) | 2023-02-17 | 2025-05-07 | Ablynx Nv | POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL |
| WO2025058962A1 (en) * | 2023-09-11 | 2025-03-20 | Absci Corporation | High-throughput methods for kinetic characterization, quantifying and optimizing antibodies and antibody fragments expression in bacteria |
| CN120737203A (zh) * | 2025-09-08 | 2025-10-03 | 南昌大学 | 抗cd38蛋白抗体及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080090414A (ko) * | 2005-12-06 | 2008-10-08 | 도만티스 리미티드 | 세포 표면 표적에 대한 결합 특이성이 있는 이중 특이성리간드 및 이의 사용방법 |
| CN103421115B (zh) * | 2013-09-02 | 2015-06-03 | 东南大学 | 一种cd38纳米抗体及应用 |
-
2016
- 2016-11-10 CN CN201680078361.5A patent/CN108884162A/zh not_active Withdrawn
- 2016-11-10 MA MA043219A patent/MA43219A/fr unknown
- 2016-11-10 EP EP16800902.5A patent/EP3374397A2/en active Pending
- 2016-11-10 JP JP2018524281A patent/JP2019503167A/ja active Pending
- 2016-11-10 WO PCT/EP2016/077361 patent/WO2017081211A2/en not_active Ceased
- 2016-11-10 US US15/774,919 patent/US10865249B2/en active Active
- 2016-11-10 AU AU2016352676A patent/AU2016352676A1/en not_active Abandoned
- 2016-11-10 CA CA3004792A patent/CA3004792A1/en active Pending
-
2020
- 2020-12-11 US US17/119,073 patent/US12018088B2/en active Active
-
2024
- 2024-06-24 US US18/752,283 patent/US20240336700A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019503167A5 (OSRAM) | ||
| JP2020536888A5 (OSRAM) | ||
| JP2020501550A5 (OSRAM) | ||
| JP2014513953A5 (OSRAM) | ||
| JP7304320B2 (ja) | 抗Ｐｒｅ－Ｓ１ ＨＢＶ抗体 | |
| JP2007514419A5 (OSRAM) | ||
| JP2017099391A5 (OSRAM) | ||
| JP2017522903A5 (OSRAM) | ||
| JP2014519487A5 (OSRAM) | ||
| WO2016197497A1 (zh) | 一种抗pd-1的单克隆抗体及其获得方法 | |
| JP2014530611A5 (OSRAM) | ||
| JP2008508864A5 (OSRAM) | ||
| JP2018537421A5 (OSRAM) | ||
| JP2012100667A5 (OSRAM) | ||
| JP2010511056A5 (OSRAM) | ||
| JP2023120208A5 (OSRAM) | ||
| CN111615519B (zh) | 结合人il-5的单克隆抗体、其制备方法和用途 | |
| Vaccarelli et al. | Generation of diversity by somatic mutation in the C amelus dromedarius T‐cell receptor gamma variable domains | |
| WO2017092375A1 (zh) | 一种能与人内皮素受体特异性结合的抗体及其应用 | |
| JP2011518857A5 (OSRAM) | ||
| CN107880117A (zh) | 识别人乙型肝炎病毒x蛋白的单克隆抗体及用途 | |
| JPH10257893A5 (OSRAM) | ||
| EP2951198A1 (en) | Inhibition of the complement system | |
| CN112040982A (zh) | 抗s100a8/a9抗体及其用途 | |
| JP2019534893A5 (OSRAM) |